Mechanisms underlying ovarian cancer initiation and progression are unclear. Herein, we report that the Yes-associated protein (YAP), a major effector of the Hippo tumor suppressor pathway, interacts with ERBB signaling pathways to regulate the initiation and progression of ovarian cancer. Immunohistochemistry studies indicate that YAP expression is associated with poor clinical outcomes in patients. Overexpression or constitutive activation of YAP leads to transformation and tumorigenesis in human ovarian surface epithelial cells, and promotes growth of cancer cells in vivo and in vitro. YAP induces the expression of epidermal growth factor (EGF)
INTRODUCTION
According to an American Cancer Society estimate for the year 2014, approximately 21 980 new cases of ovarian cancer will be diagnosed and 14 270 women will die of this disease in the United States alone. 1 Despite decades of research and evolving treatment modalities, the 5-year survival rate of ovarian cancer is still around 40%. However, if patients are diagnosed in early stages, when tumor cells are confined to the ovary, the 5-year survival rate rises to 94%. 2 The reality is that molecular markers or events that facilitate early diagnosis of ovarian cancer have not yet been established.
The Hippo pathway was initially described in Drosophila. 3, 4 Subsequent studies have shown that the Hippo pathway is conserved among species. 5, 6 Yes-associated protein (YAP1 or more commonly YAP) is a transcriptional co-activator and the pivotal effector of the Hippo pathway. 5, 6 Suppression of the Hippo pathway or overexpression of YAP can lead to organ overgrowth and tumorigenesis in model organisms. 5, 6 Recent studies have shown that YAP overexpression occurs in a broad range of human carcinomas, including lung, colorectal, breast, ovarian, pancreatic, gastric and liver cancer, [7] [8] [9] [10] [11] although differing results have been observed. 12, 13 Several groups have shown that YAP may play a role in the progression of ovarian cancer; 9, 10, 14 however, the relationships among YAP expression and clinicopathological outcomes in ovarian cancer are under debate. 9, 10, 14 Thus, the role and functional mechanism of YAP on ovarian tumorigenesis and ovarian cancer progression are not fully understood.
The actin cytoskeleton or cellular tension appears to be the master mediator that integrates and transmits upstream signals to the core Hippo signaling cascade. 6, 15 It has been proposed that activation of epidermal growth factor receptors (EGFR) promotes cell growth by changing cell polarity, affecting cell mechanotransduction and overcoming cell contact inhibition. [16] [17] [18] Indeed, studies have demonstrated that EGF stimulates YAP activity in Drosophila and MCF-10A cells, which contributes to cell proliferation. 19, 20 However, other studies have shown that EGF has no significant effect on YAP phosphorylation. 21, 22 Therefore, the role of the EGFR signaling pathway on the regulation of YAP activity remains unclear. Whether the activation of EGFR family of tyrosine kinase receptors (ERBB) and the Hippo/YAP signaling pathway interact with each other to regulate ovarian cancer progression has not been investigated.
In the present study, we examine the relationship between YAP expression and the clinicopathological outcomes of ovarian cancer with a large cohort of patient samples, and determine the role of YAP in the initiation and progression of ovarian cancer in vitro and in vivo. Our results show that the expression of YAP is associated with poor prognosis of ovarian cancer patients. Overexpression of YAP is sufficient to induce transformation of immortalized human ovarian surface epithelial cells (HOSE) and to initiate formation of ovarian tumors in vivo. Our mechanistic studies reveal the existence of an heparin-binding EGF (HBEGF) & NRGs/ERBBs/YAP/HBEGF & NRGs positive feedback loop, which may play a critical role in regulating the development and progression of ovarian cancer.
RESULTS

YAP expression is associated with poor prognosis in human ovarian cancer
To clarify the association between YAP expression and clinical outcomes of ovarian cancer patients, we quantified the expression of YAP in 42 normal human ovarian tissues and 342 ovarian cancer tissues by immunohistochemistry. The YAP immunosignal was low or undetectable in normal ovarian samples (Figures 1a and d) . In contrast, YAP levels were significantly increased in the tumor tissues, with higher level in advanced stage ovarian cancer samples (Figures 1a and d) . Both positivity and intensity of the YAP immunosignals were associated with the progression of ovarian cancer (Figures 1b and c) . YAP immunostaining was primarily detected in the nucleus of cancer cells (Figure 1d ).
To determine whether YAP expression is associated with patient survival, overall survival data of patients with ovarian cancer were stratified into two groups (low and high) based on the intensity of YAP immunosignal. Kaplan-Meier survival estimation indicated that higher YAP levels were significantly associated with poor patient overall survival (P = 0.018) (Figure 1e) . Additionally, the positivity of YAP staining significantly correlated with the primary tumor (Figure 1f) , regional lymph nodes status (Figure 1g ) and tumor metastasis (Figure 1h) . Overall, YAP expression in serous, mucinous, clear cell and endometrioid tumor tissues had no significant difference (Supplementary Figure S1a) . If the data were normalized with stage, tumor type also had no correlation with YAP expression (Supplementary Figure S1b) . YAP expression was not associated with tumor grade (Supplementary Figure S1c) .
YAP promotes proliferation of normal and cancerous ovarian cells in vitro
We prepared six human cell lines with differential YAP levels and activities to determine the effect of YAP on the proliferation of normal and cancerous ovarian cells. HOSE-YAP S127A and TOV21G-YAP S127A cell lines express constitutively activated YAP1. Table 1 ). Bars with different letters are significantly different from each other (P o0.05).
HOSE-YAP and TOV21G-YAP overexpress wild-type YAP. HOSE-MXIV and TOV21G-MXIV cells were transfected with empty vectors (MXIV) and used as controls. Western blot analysis showed that YAP was successfully overexpressed in HOSE-YAP, TOV21G-YAP, HOSE-YAP S127A and TOV21G-YAP S127A cells (Figures 2a and b) . YAP in HOSE-YAP S127A and TOV21G-YAP S127A cells were constitutively activated, which is indicated by the low level of phosphorylated YAP (Figures 2a and b) . Consistent with western blot results, HOSE-YAP, TOV21G-YAP, HOSE-YAP S127A and TOV21G-YAP1 S127A cells continue to grow in complete medium (with 10% fetal bovine serum, FBS) even after cells reached confluence; HOSE-YAP S127A and TOV21G-YAP S127A cells exhibited the highest growth rates, whereas cell growth in control groups slowed (TOV21G) or totally stopped after cells reached confluence (Figures 2a and b) .
Consistent with these results, knockdown of YAP using YAP siRNA reduced TOV21G cell proliferation (P o 0.001) (Figure 2c ). We observed that FBS suppressed YAP phosphorylation in HOSE cells (Figure 2d ). In the FBS-reduced culture medium, overexpression or constitutive activation of YAP significantly stimulated HOSE cell proliferation regardless of cell density (P o 0.01) (Figure 2e) .
In a three-dimension (3D) hanging drop culture system, HOSE-YAP S127A cells formed the largest spheroids after incubation for 16 days, whereas the HOSE-MXIV cells formed the smallest spheroids. Similarly, Ki67 was localized to almost every cell in microtissues derived from HOSE-YAP S127A cells, whereas it was localized to only few cells in microtissues derived from HOSE-MXIV cells (Figure 3a) . Verteporfin 23 not only suppressed cell proliferation (Supplementary Figure S2a) , but also disrupted cell-cell To determine whether YAP also enhanced cancer cell growth in vivo, TOV21G-MXIV, TOV21G-YAP and TOV21G-YAP S127A cells were also injected subcutaneously into athymic nude mice. As expected, all three cell lines formed tumors in the athymic mice. In comparison with the controls, tumors derived from TOV21G-YAP and TOV21G-YAP S127A cells grew dramatically faster (Figure 5b ). The tumor size and weight in these two groups were significantly increased (P o0.001; Figure 5c ). Immunofluorescent histochemistry analysis showed that YAP immunosignals in tumor tissues derived from TOV21G-YAP and TOV21G-YAP S127A cells were stronger than in control tissues (derived from TOV21G-MXIV cells) (Figure 5d ). Moreover, the YAP immunosignal was primarily located to the nucleus of tumor cells (Figure 5d ). Consistent with these results, the Ki67 immunostaining in tumor tissues derived from TOV21G-YAP and TOV21G-YAP S127A tumors was considerably greater than staining present in tumors derived from the control cell line (TOV21G-MXIV) (Figure 5e, Supplementary Figure S3 ).
YAP regulates expression of EGF-like ligands and ERBB receptors Amphiregulin (AREG), an EGFR ligand, has been identified as a YAP target gene in breast epithelial cells. 24, 25 However, overexpression of YAP did not affect AREG mRNA expression in HOSE, TOV21G and KGN cells (Figure 6a, Supplementary Figure S4) . Instead, we found that YAP overexpression or activation drastically increased mRNA levels of two ERBB receptors, EGFR and ERBB3, and three ligands, HBEGF, Neuregulin-1 (NRG1) and Neuregulin-2 (NRG2) in these cell lines ( To test whether YAP also regulated ERBB receptors and ligands in vivo, we used immunofluorescent histochemistry and/or RT-PCR to determine the expression of HBEGF, NRG1, NRG2, EGFR and ERBB3 expression in human tumor xenografts (derived from TOV21G-MXIV, TOV21G-YAP and TOV21G-YAP S127A ) in the athymic nude mice. The results showed that the protein levels of EGFR and ERBB3, and the mRNA levels of HBEGF, NRG1, NRG2, EGFR and ERBB3 were dramatically induced in tumor xenografts derived from TOV21G-YAP and TOV21G-YAP S127A cells compared with that of the control group (from TOV21G-MXIV cells) (Figures 6c and d) .
We have also found that YAP regulates the expression of ERBB3, and the production of HBEGF and NRGs may depend on its interaction with transcription factor TEAD, because treatment of HOSE-MXIV, HOSE-YAP and HOSE-YAP S127A cells with 5μM verteporfin, which inhibits the interaction between YAP and TEAD, 23 significantly blocked YAP-induced mRNA expression of ERBB3, HBEGF, NRG1 and NRG2 (Supplementary Figure S10) . Most importantly, blocking the interaction of YAP and TEAD with verteporfin drastically reduced the production of free HBEGF in the both 2D and 3D culture system, and eliminated the secretion of NRG1 in both 2D and 3D culture system (Supplementary Figure S10) .
Interactions between YAP and ERBB pathways regulate ovarian cell proliferation Because HBEGF specifically binds to EGFR and ERBB4, whereas NRG1 and NRG2 specifically bind to ERBB3 and ERBB4 to regulate cancer cell proliferation, 26 we designed experiments to determine whether these ligands and receptors are involved in YAPmediated ovarian cancer cell growth. Treatment with recombinant human NRG1-β1 and HBEGF significantly increased TOV21G and KGN cells proliferation (Figures 7a and b) . Moreover, HBEGF and NRG1-β1 also significantly stimulated proliferation of HOSE cell in a more physiological-relevant 3D handing drop culture system (Figures 7c and d) .
Knockdown of HBEGF in HOSE and TOV21G cells with different YAP activity levels partially but significantly blocked YAP-induced cell proliferation (Figures 7e and f, Supplementary Figure S11) . However, knockdown of ERBB3 completely blocked YAP-induced proliferation of HOSE and TOV21G cells with different YAP activities (Figures 7e and f, Supplementary Figure S11 ). These results suggest that the ERBB receptors and ligands contributed to YAP-mediated cell proliferation in both normal and cancerous ovarian cells.
In addition, knockdown of HBEGF or ERBB3 dramatically reversed oncogenic transformation in HOSE cells and inhibited YAP-induced enhancement of anchorage-independent growth of TOV21G cells, as indicated by a significant decrease in the colony formation induced by YAP overexpression or constitutive activation (P o0.0001) (Figures 8a and d) , indicating that ERBB3 and HBEGF contribute to YAP-mediated anchorage-independent cell growth.
The interaction between the Hippo/YAP and the ERBB signaling pathways is required for HBEGF and NRG1 stimulation of ovarian cancer cell growth In confluent TOV21G ovarian cancer cells, YAP was highly phosphorylated following serum starvation. Treatment of confluent TOV21G cancer cells with HBEGF and NRG1β1 resulted in a rapid and significant decrease in phosphorylation of LATS1, MOB1 and YAP (Figure 9a, Supplementary Figure S12 ). This evidence indicates that the Hippo pathway may be involved in mediation of the HBEGF-and NRG1-activated ERBB signals in the ovarian cancer cells, because LATS1 and MOB1 are main components of the Hippo/YAP pathway. HBEGF and NRG1β1 also induced rapid phosphorylation of ERBB receptors and activation of the PI3K and MAPK pathways in TOV21G cells (Supplementary Figures S13 and S14) . Blockade of EGFR (with AG1478), PI3K (with LY294002) or MEK1/2 (with UO126) eliminates HBEGF-and NRG1-induced dephosphorylation of YAP (Supplementary Figure S15) , suggesting the involvement of PI3K and MAPK signaling pathway in the Figure S16) . MAPK may only be partially involved in the YAP-induced transformation of ovarian surface epithelial cells because UO126 only partially blocked YAPinduced colony formation in HOSE-YAP and HOSE-YAP S127A cells (Supplementary Figure S16) .
Knockdown of HBEGF or ERBB3 blocked YAP-induced formation of spheroids by HOSE cells and suppressed the growth of HOSE cells in the 3D culture system (Figure 9b) . Knockdown of YAP not only eliminated HBEGF-and NRG1β1-induced TOV21G cell proliferation, but also suppressed the basal proliferation of TOV21G cells (Figure 9c) . Similar results were observed in KGN cells (Figure 9d) . Intriguingly, treatment of confluent TOV21G cells with HBEGF and NRG1β1 for 48 h stimulated the transcription of ERBB3, HBEGF, NRG1 and NRG2 genes (Supplementary Figure S17) . DISCUSSION YAP has been identified as the essential downstream effector of the Hippo pathway. YAP is frequently upregulated in a wide spectrum of human solid tumors and significantly associated with poor clinical outcomes. 10, [27] [28] [29] In ovarian cancer, the relationship between YAP expression and clinical outcomes is somewhat controversial. Hall et al. 9 reported that high levels of nuclear YAP, or low levels of cytoplasmic phosphorylated YAP, is associated with poor survival of ovarian cancer patients. 30 However, Zhang et al. 10 did not observe any association between YAP expression and clinical outcomes in serous cancers. In their study, correlation between nuclear YAP and poor survival is limited to patients with ovarian clear cell carcinoma. The discrepancy can be attributed to the relatively small sample size in these studies. In the present study, using a large cohort of patient samples, we found that total YAP staining was significantly associated with poor patient survival. Further analysis showed that total YAP staining was strongly correlated with stage and TNM status (tumor, lymph node and metastasis staging). Our results are consistent with previous reports in multiple human cancers, 28, 31, 32 and indicate that YAP activity may play a causal role on ovarian cancer progression and metastasis. Nevertheless, we realize the limitation of immunohistochemistry-based detection and analysis systems. The utility of YAP as an independent prognostic marker of ovarian cancer needs to be extensively verified using additional approaches.
Human ovarian cancer has been traditionally thought to originate from HOSE cells; 33 although recent studies indicate that fallopian tube epithelial cells might also be an origin for serious ovarian epithelial cancer. 34 Disruption of TP53 and RB1 pathway by SV40 early genomic region and hTERT immortalized but did not transform HOSE cells. 36 Introduction of HRAS V12 or KRAS V12 into the immortalized cells, however, allowed them to form subcutaneous tumors after injection into immunocompromised mice. 36 In the present study, we found that overexpression of wild-type YAP or constitutively active YAP was sufficient for transformation of immortalized normal HOSE cells. Our study also indicated that overexpression of wild-type YAP or constitutively active YAP promoted cancerous ovarian epithelial cell growth both in vivo and in vitro, consistent with previous in vitro studies showing that YAP acts as an ovarian oncogene. 3, 9, 36 Hall et al. 9 showed that overexpression of YAP
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(in which all five serine phosphorylation sites in YAP gene were mutated to alanine) was able to induce the colony formation in ovarian surface epithelial cells. Our present study is the first direct in vivo evidence showing that overexpression of YAP in HOSE cells is sufficient to initiate tumors. Our study clearly shows that overexpression of YAP is a potential event for initiation and progression of ovarian cancer. As HOSE-T80 cells are immortalized with SV40T/t and hTERT, 36 we cannot exclude a synergetic effect of YAP with the viral genes on the tumorigenicity of HOSE cells. Recently, Sasaki et al. 37 established an immortalized HOSE cells by expressing mutant Cdk4, cyclin D1 and hTERT. As this HOSE cell line was immortalized without involvement of virus, it may be a valuable tool for studying the role of YAP in the transformation of HOSE.
The mechanism underlying YAP regulation of initiation and progression of ovarian cancer is unclear. One recent report suggested that YAP-stimulated production of AREG in ovarian cancer cells can regulate ovarian cancer progression.
14 However, other investigators showed that overexpression or activation of YAP had no effect on AREG expression. 7, 9 Similarly, we found that AREG expression was not affected by overexpression or activation of YAP in HOSE-T80, TOV21G and KGN cells. However, we did find a significant increase in AREG expression in cervical cancer cells after YAP overexpression (He and Wang, unpublished data). By examining the mRNA expression profile of all EGF-like ligands and ERBBs in our YAP activity-modified cell lines, we found that expression of HBEGF, NRG1 and NRG2 was consistently upregulated by YAP in HOSE and ovarian cancer cell lines ( Figure 6 , Supplementary Figure S4 -S7). It is known that HBEGF signals through EGFR and ERBB4, whereas NRG1 signals through ERBB3 and ERBB4. Although interaction between YAP and ERBB4 has been reported previously, 38, 39 our results show that in the receptor level, only EGFR and ERBB3 are consistently upregulated by YAP overexpression or constitutive activation in the ovarian cells. ERBB2 level was not significantly changed by YAP expression or activation, whereas ERBB4 is regulated by YAP protein in a celltype-dependent manner. Therefore, in the ovarian cancer cells, the Hippo/YAP signaling pathway may interact with the ERBB signaling pathway, especially the HBEGF-and neuregulinactivated EGFR and ERBB3 signaling pathways, to drive the initiation and progression of ovarian cancer. However, a potential interaction between YAP and ErbB4, which has been reported in other cancer cell types, 38, 39 may also exist in the ovarian cancer cells and deserves further investigations.
Expressions of EGFR, ERBB3, HBEGF, NRG1 and NRG2 have been implicated in both normal organ development and malignancy. 26 The expression and function of EGFR and ERBB2 in breast and ovarian cancer have been extensively studied. However, roles of ERBB3 in ovarian cancer initiation and progression are not well defined. A recent study showed that in a portion (~25%) of ovarian cancers, NRG1 activated ERBB3 to promote cancer cell proliferation and drive tumor growth. 40 Consistent with this finding, in the present study, we found that NRG1 was able to promote TOV21G and KGN cell proliferation (Figures 7a and b) . Interestingly, we found that overexpression of YAP or constitutively active YAP in TOV21G or KGN ovarian tumor cells dramatically induced NRG1 production and ERBB3 expression. Knockdown of ERBB3 eliminated the stimulatory effect of YAP on cancer cell proliferation (Figures 7e and f) , and nearly abrogated YAP-enhanced anchorage-independent growth of TOV21G cells. These results clearly indicate that YAP has the potential to control ovarian cancer cell proliferation via regulating the NRG1/ERBB3 pathway. Intriguingly, we found that NRG1 was able to rapidly suppress Hippo pathway and activate YAP by dephosphorylating LATS1, MOB1 and YAP (Figure 9 ). Simultaneously, NRG1 also stimulated the expression of ERBB3, NRG1, NRG2 and HBEGF. Knockdown of YAP in ovarian cancer cells suppressed the basal growth in these cells and eliminated NRG1-stimulated cancer cell proliferation ( Figure 9 ). Taken together, our data indicate the existence of an NRG1/ERBB3/YAP/NRG1 autocrine loop in the ovarian cancer cells. This autocrine loop appears to play a critical role in the initiation and progression of ovarian cancers. HBEGF has been shown to play a critical role in the ovarian tumorigenesis and tumor progression. 41 In the present study, we found that overexpression or constitutive activation of YAP also increased production of free HBEGF and expression of EGFR (the selective receptor for HBEGF). Knockdown of YAP in cancer cells suppressed production of free HBEGF and expression of EGFR. Like NRG1, HBEGF also stimulated ovarian cancer cell growth. Moreover, HBEGF was able to suppressed phosphorylation of LATS1, MOB1 and YAP and stimulate production of NRG1 and free HBEGF, and expression of ERBB3. These results suggest the potential presence of a pro-proliferation HBEGF/EGFR/YAP/HBEGF autocrine loop in the ovarian cancer cells. A recent report indicates that the EGFR-RAS-MAPK signaling promotes phosphorylation of the Ajuba family protein WTIP and thus enhances WTIP binding to LATS and WW45, leading to suppression of Hippo pathway and activation of YAP. 20 This evidence strongly supports our findings. Interestingly, we found that treatment of TOV21G with HBEGF within 2 h, but not NRG1, nearly eliminated the expression of EGFR receptor ( Supplementary Figures S13 and S14 ). This observation is consistent with previous finding that HBEGF binding lead to the rapid lysosomal degradation of EGFR. 42 Therefore, HBEGF and neuregulin may regulate ovarian cancer progression in different ways: neuregulin constitutively stimulates ovarian cancer progression through a positive autocrine/paracrine loop, whereas HBEGF may amplify the NRG1/ERBB3/YAP/NRG1 autocrine loop.
YAP has been showed to act mainly through its direct interaction with TEAD/TEF family to regulate downstream genes expression. 5, 6 Verteporfin is a selective antagonist of YAP functioning that acts by interrupting YAP-TEAD interaction. Our data show that verteporfin not only inhibited YAP-induced transformation of ovarian surface epithelial cells, suppressed YAPenhanced growth of normal and ovarian cancer cells, but also blocked YAP-induced production of free HBEGF and NRG1, as well as expression of ERBB3 receptor. Clearly, YAP regulation of the initiation and progression of ovarian cancer may depend on its proper interaction with the TEAD transcription factor. Recent studies showed that beside TEAD, YAP also interacts with others transcriptional factors, such as Smad, Runx1/2, p73, Pax3 and TBX5 (a list that is still rapid growing), to regulate downstream gene expression. 5, 6 These transcription factors may also be important for the ovarian cancer initiation and progression and need further studies.
In conclusion, our present study shows that YAP has the potential to transform the ovarian surface epithelial cells, leading to initiation and progression of ovarian cancer. YAP (potentially in a Hippo pathway-dependent manner) forms autocrine loops with the ERBB signaling pathway to induce the initiation and promote the progression of ovarian cancer (Figure 10 ). Although upregulation of EGFR, ERBB2 and ERBB3 is found in 60%, 18% and 50% of epithelial ovarian cancer tissues, respectively, the clinical trial results with single agent EGFR inhibitors such as erlotinib, getitinib, trastuzumab or pertuzumab, have proven to be of little benefit in randomized trials. 43 The identification of a NRG1/ERBB3/ YAP/NRG1 autocrine loop in ovarian cancers suggests that ERBB3 will be a promising target for ovarian cancer. MM-121, a monoclonal ERBB3-directed antibody, is currently under investigation in phase II trials. Combined targeting of the Hippo/YAP pathway and ERBB pathways, especially the NRG1/ERBB3 pathway, has potential to provide a novel therapeutic strategy for ovarian cancer treatment. 
MATERIALS AND METHODS
Immunohistochemistry
YAP expression in ovarian tissues was detected using a peroxidase-based immunohistochemistry, the immunosignal was visualized with DAB kit (Invitrogen, Carlsbad, CA, USA). Sections were scanned with an iSCAN Coreo Slide Scaner (Ventana Medical Systems, Inc., Oro Valley, AZ, USA). The intensity of the positive signal was quantified using Aperio ImageScope software (Aperio Technologies, Inc., Vista, CA, USA).
Cell transfection
Nine cell lines were established to determine the effect of YAP on ovarian cancer cell proliferation. Briefly, HOSET80, TOV21G and KGN cells were cultured to 40% confluence and then transfected with retrovirus-based YAP overexpression constructs (YAP, YAP S127A ) or empty vector (MXIV). Stable transfected clones were selected using G418. Cell growth was determined by counting the cell number using an Invitrogen Countess Automated cell counter (Invitrogen).
3D hanging drop cell culture and colony formation assays Two 3D hanging drop culture systems were used to examine the role of YAP in the cell proliferation and cell-cell communication. Briefly, cells (0.5 × 10 6 ) were cultured in Perfecta3D (3D Biomatrix, Ann Arbor, MI, USA) or GravityPLUS 3D Cell Culture plates (InSphero, Schlieren, Switzerland) according to the manufacturer's instruction. Cytoselect 96-Well Cell Transformation assay kit (Cell Biolabs, Inc., San Diego, CA, USA) was used to determine the effect of YAP on the anchorage-independent growth of ovarian cells.
RT-PCR and western blot analysis
Total RNA was prepared by RNeasy Mini Kit (QIAGEN, Valencia, CA, USA), and reverse transcription was completed by using SuperScript First-Strand kit (Life Technologies). RT-PCR was run on MJ PTC100 Programmable Thermal cycler (Bio-Rad Laboratories, Hercules, CA, USA) with a protocol established in our laboratory. 44, 45 The primers have been validated previously. 46 Protein levels were determined by western blot with a protocol established in our laboratory. 44, 45 The immunosignal was detected by using The SuperSignal West Femto Chemiluminescent Substrate Kit (Pierce/Thermo Scientific, Rockford, IL, USA); the images were captured and analyzed with a UVP gel documentation system (UVP, LLC, Upland, CA, USA).
In vivo tumorigenicity
A total of 5 × 10 6 cells/0.1 ml PBS were injected subcutaneously into the dorsal flank of 7-week-old female athymic nude mice (n = 5). Tumor volume (mm 3 ) was calculated as follows: volume = (shortest diameter) 2 × (longest diameter) × 3.14÷6. The animal handling procedures and all experimental protocols were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Nebraska Medical Center.
Immunofluorescent histochemistry
Frozen sections at 6 μm were stained with a protocol established in our laboratory. 44, 45 Images were captured using a Zeiss 710 Meta Confocal Laser Scanning Microscope and analyzed using the Zeiss Zen 2010 software (Carl Zeiss Microscopy, LLC, Thornwood, NY, USA). TUNEL assay was performed using TUNEL Apoptosis Detection kit (EMD Millipore, Inc. Darmstadt, Germany) to determine cell apoptosis.
Statistical analysis
All experiments were repeated at least three times unless otherwise noted. Statistical analyses were conducted primarily using GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA, USA). Data were analyzed for significance by one-way analysis of variance with Tukey's post hoc test. A value of Po 0.05 was considered to be significant. 
